✦ LIBER ✦

Mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction in liver transplant: A 24-month controlled clinical trial

✍ Scribed by M. Biselli; G. Vitale; A. Gramenzi; A. Riili; S. Berardi; F. Dazzani; C. Cammà; A. Scuteri; M.C. Morelli; C. Sama; G.L. Grazi; A.D. Pinna; P. Andreone; M. Bernardi

Book ID: 119228656
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 58 KB
Volume: 39
Category: Article
ISSN: 1590-8658
DOI: 10.1016/j.dld.2007.07.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Two yr mycophenolate mofetil plus low-do

Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant

✍ Maurizio Biselli; Giovanni Vitale; Annagiulia Gramenzi; Anna Riili; Sonia Berard 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB

Replacement of calcineurin inhibitors wi

Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study

✍ Hans J Schlitt; Annette Barkmann; Klaus HW Böker; Nikos Emmanouilidis; Jens Rose 📂 Article 📅 2001 🏛 The Lancet 🌐 English ⚖ 84 KB

Improvement of Renal Function After Conv

Improvement of Renal Function After Conversion to Mycophenolate Mofetil Combined With Low-Level Calcineurin Inhibitor in Liver Transplant Recipients With Chronic Renal Dysfunction

✍ C. Ponton; L. Vizcaíno; S. Tomé; E. Otero; E. Molina; J.F. Castroagudín; A. Lópe 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 195 KB

138 Mycophenolate mofetil (MMF) in combi

138 Mycophenolate mofetil (MMF) in combination with calcineurin inhibitors (CNI) for chronic renal dysfunction after liver transplantation: A prospective, randomized study

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 116 KB

Clinical trial: switch to combined mycop

Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients – assessment of renal and allograft function, cardiovascular risk factors and immune monitoring

✍ V. R. CICINNATI; Z. YU; C. G. KLEIN; G. C. SOTIROPOULOS; F. SANER; M. MALAGÓ; A. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 238 KB

Evaluation of renal function in liver tr

Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized clinical trial

✍ Eric M. Yoshida; Paul J. Marotta; Paul D. Greig; Norman M. Kneteman; Denis Marle 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 111 KB

Posttransplant chronic renal failure, secondary to calcineurin inhibitor agents, is emerging as a major problem in liver transplantation. We report a randomized clinical trial comparing daclizumab, delayed low-dose tacrolimus (target trough level 4-8 ng/mL, starting day 4-6), Investigational Arm (n